Market Inference Reports — Moderna (MRNA) Stock

Shares of Moderna have moved -6.4% today, and are now trading at a price of $166.08. In contrast, the S&P 500 index saw a 0.5% change and the Dow Industrial Average posted a 0.2% performance. Today's trading volume is 1,801,320 compared to the stock's average volume of 4,706,177.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Based in Cambridge, United States the company has 3,700 full time employees and a market cap of $63,804,616,704.

The company is now trading -20.71% away from its average analyst target price of $209.47 per share. The 15 analysts following the stock have set target prices ranging from $101 to $506, and on average give Moderna a rating of buy.

Over the last year, MRNA shares have gone down by -34.8%, which represents a difference of -19.1% when compared to the S&P 500. The stock's 52 week high is $321.31 per share and its 52 week low is $115.03. Based on Moderna's average gross margin growth of 29.1% over the last four years, its core business remains strong and the stock price may recover in the long term.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.